hotspot -WSS

hotspot

author：leisure time 2025-09-28 02:47:51 - browse：96284

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Biogen joins immunology wave with $1.15 billion acquisition of HI

explore

hotspot

WSS

What will Novo Nordisk's VC do with its influx of cash?

Listen: More tumult at BIO & coercive care for sickle cell patients

RSV injection headlines need to be accurate for good uptake

Addressing health care workers' trauma can help fight burnout

Some top drug companies are starting to take action on climate

Listen: More tumult at BIO & coercive care for sickle cell patients

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Supreme Court strikes down use of affirmative action

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Dobbs anniversary: the lost opportunity of abortion as health care

Study finds gene variants tied to breast cancer risk in Black women

Peter Hotez and the public health issue of online harassment

The United States is paying nearly triple for new Covid vaccines

Jerome Adams on the need for new antivirals for Covid

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

explore

CRISPR base editing slashes cholesterol levels in monkeys

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Making the case for fair compensation in clinical trials

European officials brace for rough respiratory virus season

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

The biotech scorecard for Q4: 16 stock

explore

entertainment

hotspot

focus